RxDoctor Payments Data

Guillermo Cuna, MD

Family Medicine · Fort Myers, FLNPI 1124024047

Payments from drug & device makers

$1,771in general payments, 2019–2025

Across 93 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$520
  • Johnson & Johnson$291
  • AstraZeneca$201
  • GSK$126
  • Merck$121
  • Takeda Pharmaceuticals U.S.A., Inc.$105
  • plus $406 from 11 others

What the payments were for

  • Food & beverage$1,764100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,771 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$10,170
Medicare patients
85
Services billed
107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide152$193,714
EliquisApixaban67$68,601
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$44,652
JanuviaSitagliptin Phosphate24$35,136
XareltoRivaroxaban33$28,398
LinzessLinaclotide18$22,984
JardianceEmpagliflozin14$22,758
Breo ElliptaFluticasone/Vilanterol34$22,510
TradjentaLinagliptin18$15,928
Tresiba Flextouch U-200Insulin Degludec16$15,858
MyrbetriqMirabegron17$11,728
Bydureon BciseExenatide Microspheres13$10,075
Praluent PenAlirocumab13$9,650
Repatha SureclickEvolocumab11$9,063
JanumetSitagliptin Phos/Metformin Hcl14$8,056

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$520$193,714152 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$126$73,493106 claims
PfizerEliquis$95$68,60167 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$29$44,33744 claims
MerckJanuvia, Janumet$121$43,19138 claims
Johnson & JohnsonXarelto$291$28,39833 claims
Astellas Pharma US IncMyrbetriq$36$11,72817 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$105$7,50211 claims
AstraZenecaSymbicort$201$5,34611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →